AIM (AIM ImmunoTech) Institutional Ownership: 1.33% (As of Jul. 13, 2026)


AIM AIM ImmunoTech Inc AIM
33 GF Score
Price $0.28
GF Value $2.53
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Institutional Ownership?

AIM ImmunoTech AIM -2.38% 33 Institutional Ownership is 1.33% as of Jul. 13, 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.53 (Possible Value Trap). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AIM ImmunoTech's institutional ownership is 1.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AIM ImmunoTech's Insider Ownership is 23.11%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AIM ImmunoTech's Float Percentage Of Total Shares Outstanding is 99.50%.

AIM ImmunoTech Institutional Ownership Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Institutional Ownership Chart

AIM ImmunoTech Historical Data

The historical data trend for AIM ImmunoTech can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 2.48 2.58 2.58 0.59 0.59 0.83 0.38 0.99 0.99 0.11
AIM
33GF Score
AIM ImmunoTech Inc AIM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.33% mean?
AIM ImmunoTech (AIM) has a Institutional Ownership of 1.33% as of Jul. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's Institutional Ownership too high?
AIM ImmunoTech's current Institutional Ownership is 1.33%. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Institutional Ownership compare to RVPH and BOLT?
AIM ImmunoTech's Institutional Ownership of 1.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Institutional Ownership is 1.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.53, compared to a current price of $0.28 — trading 88.8% below its estimated fair value. The current Institutional Ownership is 1.33%. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Institutional Ownership is 1.33% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.28 is trading 88.8% below its estimated GF Value™ of $2.53. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • Institutional Ownership: 1.33%
  • GF Value™: $2.53 vs. price of $0.28 (88.8% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for AIM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price
$2.53
GF Value